Literature DB >> 16678488

Multifaceted antiviral actions of APOBEC3 cytidine deaminases.

Ya-Lin Chiu1, Warner C Greene.   

Abstract

To defend against external pathogens, metazoan organisms have evolved numerous defenses that generally fall within the innate and adaptive immune responses. Considerable effort continues to focus on developing a vaccine to manipulate the adaptive immune system to protect against or control HIV-1. However, recent advances in our understanding of the innate immune system have revealed that cells have a potent intrinsic antiretroviral defense in the form of APOBEC3G, which is a member of a larger family of cytidine deaminases that are active against HIV-1 and other retroviruses. Insights into how the action of A3G is circumvented by HIV-1 through the action of its Vif protein, and the surprising mechanisms by which A3G is regulated within the cell, offer exciting new opportunities for developing novel anti-HIV-1 therapies that exploit this intrinsic antiretroviral system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16678488     DOI: 10.1016/j.it.2006.04.003

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  28 in total

1.  Correlation of APOBEC3G expression with liver function indexes of patients with chronic hepatitis B and comparison in chronic hepatitis B, liver cirrhosis and liver cancer.

Authors:  Lina Ni; Chuanbao Li; Yingbo Li
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

2.  Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity.

Authors:  William M McDougall; Harold C Smith
Journal:  Biochem Biophys Res Commun       Date:  2011-08-11       Impact factor: 3.575

3.  Insulin-like growth factor II mRNA binding protein 1 associates with Gag protein of human immunodeficiency virus type 1, and its overexpression affects virus assembly.

Authors:  Yongdong Zhou; Liwei Rong; Jennifer Lu; Qinghua Pan; Chen Liang
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

4.  Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo.

Authors:  Eri Takeda; Sachiyo Tsuji-Kawahara; Mayumi Sakamoto; Marc-André Langlois; Michael S Neuberger; Cristina Rada; Masaaki Miyazawa
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

5.  Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.

Authors:  Shiv K Gandhi; Janet D Siliciano; Justin R Bailey; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

6.  Species-specific restriction of apobec3-mediated hypermutation.

Authors:  Edward P Browne; Dan R Littman
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

7.  Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.

Authors:  Stefanie Andrea Knoepfel; Nadine Christina Salisch; Peter Michael Huelsmann; Pia Rauch; Hauke Walter; Karin Jutta Metzner
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism.

Authors:  Mariana Marin; Sheetal Golem; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

9.  Structural analysis of the activation-induced deoxycytidine deaminase required in immunoglobulin diversification.

Authors:  Phuong Pham; Samir A Afif; Mayuko Shimoda; Kazuhiko Maeda; Nobuo Sakaguchi; Lars C Pedersen; Myron F Goodman
Journal:  DNA Repair (Amst)       Date:  2016-05-13

10.  Astrocyte indoleamine 2,3-dioxygenase is induced by the TLR3 ligand poly(I:C): mechanism of induction and role in antiviral response.

Authors:  Hyeon-Sook Suh; Meng-Liang Zhao; Mark Rivieccio; Shinyeop Choi; Erin Connolly; Yongmei Zhao; Osamu Takikawa; Celia F Brosnan; Sunhee C Lee
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.